Tecentriq ® (atezolizumab) – New indication approval
July 31, 2020 - Roche announced the FDA approval of Tecentriq (atezolizumab), in combination with Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Top